

Biophytis Trading will resume on February 14th, 2020 at 09:00 CET

Paris (France), Cambridge (Massachusetts, U.S.), February 14, 2020, 08:00 CET - Biophytis SA (Euronext Growth Paris: ALBPS - FR0012816825) announces that trading will resume on February 14th, 2020 at 09:00 CET.

Following the stock price suspension from trading asked on February 13th before the opening of the stock exchange and the company's press release of this morning, trading will resume today at 09:00 CET.

About Biophytis

Biophytis is a clinical-stage biotechnology company focused on developing therapeutics that slow the degenerative processes associated with aging and improve functional outcomes for patients suffering from age-related diseases, with a primary focus on neuromuscular diseases.

Biophytis' lead drug candidate, Sarconeos (BIO101) is an orally administered small molecule, which is currently in a Phase 2b clinical trial for sarcopenia (SARA-INT) in the U.S. and Europe. A pediatric formulation of Sarconeos (BIO101) is being developed for the treatment of Duchenne muscular dystrophy (DMD), for which the company was granted FDA IND approval in December 2019.

Biophytis is headquartered in Paris, France, and has offices in Cambridge, Massachusetts. The Company's ordinary shares are listed on Euronext Growth Paris (Ticker: ALBPS - ISIN: FR0012816825).

For more information please visit www.biophytis.com

Biophytis Investor Relations Contact

Evelyne Nguyen, CFO
contact@biophytis.com

Europe Media Contact

Citigate Dewe Rogerson
Sylvie Berrebi / David Dible / Nathaniel Dahan / Quentin Dussart
biophytis@citigatedewerogerson.com
Tel: +33 (0)1 55 30 70 91 / +44 (0)20 76389571

Source: Biophytis